Drug Research

To Curb Medicine Inequality, 3-Year Novel Strategy Announced

A novel strategy for 2023–25 adopted by the Medicines Patent Pool looks to lessen the inequalities in access by way of enhancing the affordability as well as availability of health products across low- and-middle-income countries (LMIC). The MPP which is...

EC approves Regeneron-Sanofi’s Dupixent for eosinophilic esophagitis

The European Commission (EC) has granted marketing authorisation for Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE). Dupixent’s expanded authorisation in the European Union (EU) is intended to treat 12 years and older patients with EoE, who...

Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston

Seqens Group opens the Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. that serves as one of the company’s global centers of excellence. The new facility will bring customers advanced capabilities for the discovery...

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus Vaccine Candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the...

Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park

Eli Lilly and Company announced plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly...

SK bioscience introduces new partnership model to establish regional vaccine hubs

SK bioscience, a global innovative vaccine and biotech company, introduced a new global partnership model under the title of ‘Preparing for Next Pandemic through Global Partnership’ at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in the Kingdom...

Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, announced the opening of a new commercial-scale plasmid DNA (pDNA) manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read